Avricore Health (AVCRF) EBITDA Margin (2009 - 2025)

Avricore Health has disclosed EBITDA Margin across 16 years of filings, most recently posting 1005.97% for Q3 2025.

• In Q3 2025, EBITDA Margin fell 99099.0% year-over-year to 1005.97%; the TTM figure through Sep 2025 stood at 64.59% (down 6681.0% YoY), while the FY2025 annual figure was 348.17%, down 33419.0% from the prior year.
• EBITDA Margin advanced to 1005.97% in Q3 2025, from 1602.16% in the prior quarter.
• Over the last five years, EBITDA Margin for AVCRF reached as high as 9442.98% in Q1 2021 and fell as low as 1602.16% in Q2 2025.
• The 5-year median for EBITDA Margin is 21.43% (2022), against an average of 792.32%.
• Annual changes were most pronounced in 2021 — EBITDA Margin jumped 940500 bps — and 2022, when it plunged 987746 bps.
• A 5-year view of EBITDA Margin shows it stood at 593.62% in 2021, then sank by 104 bps to 25.05% in 2022, then surged by 118 bps to 4.4% in 2023, then plunged by 441 bps to 14.98% in 2024, then slumped by 6614 bps to 1005.97% in 2025.
• According to Business Quant data, EBITDA Margin over the past three periods registered 1005.97%, 1602.16%, and 17.81% for Q3 2025, Q2 2025, and Q1 2025 respectively.